Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection

Vaccine

Volumn 26, Issue SUPPL. 8, 2008, Pages

  Brockman, Mark A ^a   Knipe, David M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antigen presentation; Immune evasion; Innate immunity

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT RECEPTOR; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW CELL; COMPLEMENT SYSTEM; GENE EXPRESSION; HERPES SIMPLEX VIRUS; HUMORAL IMMUNITY; IMMUNE ESCAPE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINE PRODUCTION; VIRUS MUTANT; VIRUS PATHOGENESIS;

ANTIBODIES, VIRAL; COMPLEMENT C3; HERPES SIMPLEX; HUMANS; IMMUNITY, INNATE; MYELOID CELLS; RECEPTORS, COMPLEMENT 3D; SIMPLEXVIRUS;

EID: 57649220609     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.062     Document Type: Article

References (104)

1. Letvin N.L., and Walker B.D. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 9 (2003) 861-866
2. Davenport M.P., Ribeiro R.M., Chao D.L., and Perelson A.S. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol 78 (2004) 11340-11351
3. Da Costa X.J., Brockman M.A., Alicot E., Ma M., Fischer M.B., Zhou X., et al. Humoral response to herpes simplex virus is complement-dependent. Proc Natl Acad Sci USA 96 (1999) 12708-12712
4. Verschoor A., Brockman M.A., Knipe D.M., and Carroll M.C. Cutting edge: Myeloid complement c3 enhances the humoral response to peripheral viral infection. J Immunol 167 (2001) 2446-2451
5. Gadjeva M., Verschoor A., Brockman M.A., Jezak H., Shen L.M., Knipe D.M., et al. Macrophage-derived complement component C4 can restore humoral immunity in C4-deficient mice. J Immunol 169 (2002) 5489-5495
6. Verschoor A., Brockman M.A., Gadjeva M.A., Knipe D.M., and Carroll M.C. Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection. J Immunol 171 (2003) 5363-5371
7. Brockman M.A., Verschoor A., Zhu J., Carroll M.C., and Knipe D.M. Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells. J Virol 80 (2006) 7111-7117
8. Heise M.T., and Virgin IV H.W. The T-cell-independent role of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infections. J Virol 69 (1995) 904-909
9. Sarmiento M. Intrinsic resistance to viral infection. Mouse macrophage restriction of herpes simplex virus replication. J Immunol 141 8 (1988) 2740-2748
10. Orange J.S., and Biron C.A. An absolute and restricted requirement for IL-12 in natural killer cell INF-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections. J Immunol 156 (1996) 1138-1142
11. Rager-Zisman B., Quan P.C., Rosner M., Moller J.R., and Bloom B.R. Role of NK cells in protection of mice against herpes simplex virus-1 infection. J Immunol 138 (1987) 884-888
12. Welsh R.M., Dundun P.L., Eynon E.E., Brubaker J.O., Koo G.C., and O'Donnell C.L. Demonstration of the antiviral role of natural killer cells in vivo with a natural killer cell-specific monoclonal antibody (NK1.1). Nat Immun Cell Growth Regulat 9 (1990) 112-120
13. Kadowaki N., Antonenko S., Lau J.Y., and Liu Y.J. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 192 (2000) 219-226
14. van Vliet S.J., den Dunnen J., Gringhuis S.I., Geijtenbeek T.B., and van Kooyk Y. Innate signaling and regulation of Dendritic cell immunity. Curr Opin Immunol (2007) 19
15. Geijtenbeek T.B., van Vliet S.J., Engering A., 't Hart B.A., and van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 22 (2004) 33-54
16. Baumgarth N., Herman O.C., Jager G.C., Brown L., and Herzenberg L.A. Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. Proc Natl Acad Sci USA 96 (1999) 2250-2255
17. Ochsenbein A.F., Pinschewer D.D., Odermatt B., Carroll M.C., Hengartner H., and Zinkernagel R.M. Protective T cell-independent antiviral antibody responses are dependent on complement. J Exp Med 190 (1999) 1165-1174
18. Parr E.L., and Parr M.B. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology 98 (1999) 639-645
19. Suzutani T., Nagamine M., Shibaki T., Ogasawara M., Yoshida I., Daikoku T., et al. The role of the UL41 gene of herpes simplex virus type 1 evasion of non-specific host defence mechanisms during primary infection. J Gen Virol 81 (2000) 1763-1771
20. Anderson D.R., Carthy C.M., Wilson J.E., Yang D., Devine D.V., and McManus B.M. Complement component C3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers. J Virol 71 (1997) 8841-8885
21. Boere W.A., Benaissa-Trouw B.J., Harmsen T., Erich T., Kraaijeveld C.A., and Snippe H. The role of complement in monoclonal antibody-mediated protection against virulent Semliki Forest virus. Immunology 58 (1986) 553-559
22. Morgan B.P., Marchbank K.J., Longhi M.P., Harris C.L., and Gallimore A.M. Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett 97 (2005) 171-179
23. Carroll M.C. The complement system in regulation of adaptive immunity. Nat Immunol 5 (2004) 981-986
24. Heyman B., Pilstrom L., and Shulman M. Complement activation is required for IgM-mediated enhancement of the antibody response. J Exp Med 167 (1988) 1999-2004
25. Boes M., Prodeus A., Schmidt T., Carroll M.C., and Chen J. A critical role of natural IgM in immediate response against systemic bacterial infection. J Exp Med 188 (1998) 2381-2386
26. Epstein J., Eichbaum Q.E., Sheriff S., and Ezekowitz R.A.B. The collectins in innate immunity. Curr Opin Immunol 8 (1996) 29-35
27. Law S.K., Lichtenberg N.A., and Levine R.P. Covalent binding and hemolytic activity of complement proteins. Proc Natl Acad Sci USA 77 (1980) 7194-7198
28. Tack B.F., Harrison R.A., Janatova J., Thomas M.L., and Prahl J.W. Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA 77 (1980) 5764-5768
29. Devaux P., Christiansen D., Fontaine M., and Gerlier D. Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation. Eur J Immunol 29 (1999) 815-822
30. Feldbush T.L., Hobbs M.V., Severson C.D., Ballas Z.K., and Weiler J.M. Role of complement in the immune response. Fed Proc 43 (1984) 2548-2552
31. Fleisher T.A., and Berger M. Immunoregulatory effects of C3 and its major cleavage fragments. Clin Immunol Immunopathol 33 (1984) 391-401
32. Daffern P.J., Pfeifer P.H., Ember J.A., and Hugli T.E. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 181 (1995) 2119-2127
33. Hartmann K., Henz B.M., Krüger-Krasagakes S., Köhl J., Burger R., Guhl S., et al. C3a and C5a stimulate chemotaxis of human mast cells. Blood 89 (1997) 2863-2870
34. Hirsh R.L. The complement system. Microbiol Rev 46 (1982) 71-85
35. Prodinger W.M., Wurzner R., Erdei A., and Dierich M.P. Complement. In: Paul W.E. (Ed). Fundamental immunology. 4th ed. (1999), Lippencott-Raven, Philiadelphia 967-995
36. Pepys M.B. Role of complement in the induction of immunological responses. Transplantat Rev 32 (1976) 93-120
37. Brown E.J. The interaction of small oligomers of complement 3B (C3B) with phagocytes. High affinity binding and phorbol ester-induced internalization by polymorphonuclear leukocytes. J Biol Chem 264 (1989) 6196-6201
38. Tew J.G., Mandel T.E., and Miller G.A. Immune retention: immunological requirements for maintaining an easily degradable antigen in vivo. Aust J Exp Biol Med Sci 57 (1979) 401-414
39. Clemenza L., and Isenman D.E. Structure-guided identification of C3d residues essential for its binding to complement receptor 2. J Immunol 165 (2000) 3839-3848
40. Molina H., Kinoshita T., Webster C.B., and Holers V.M. Analysis of C3b/C3d binding sites and factor I cofactor regions within the mouse complement receptors 1 and 2. J Immunol 153 (1994) 789-795
41. Qin D., Wu J., Carroll M.C., Burton G.F., Szakal A.K., and Tew J.G. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J Immunol 161 (1998) 4549-4554
42. Mongini P.K., Vilensky M.A., Highet P.F., and Inman J.K. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J Immunol 159 (1997) 3782-3791
43. Fang Y., Xu C., Fu Y.X., Holers V.M., and Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 160 (1998) 5273-5279
44. Fischer M.B., Ma M., Goerg S., Zhou X., Xia J., Finco O., et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 157 (1996) 549-556
45. Molina H., Holers V.M., Li B., Fung Y., Mariathasan S., Goellner J., et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci USA 93 (1996) 3357-3361
46. Carter R.H., and Fearon D.T. CD19: lowering the threshold for antigen receptor stimulation of B cells. Science 256 (1992) 105-107
47. Fearon D.T. The complement system and adaptive immunity. Semin Immunol 10 (1998) 355-361
48. Ahearn J.M., Fischer M.B., Croix D.A., Goerg S., Ma M., Xia J., et al. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 4 (1996) 251-262
49. Engel P., Zhou L.J., Ord D.C., Sato S., Koller B., and Tedder T.F. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3 (1995) 39-50
50. Rickert R.C., Rajewsky K., and Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376 (1995) 352-355
51. Dempsey P.W., Allison M.E.D., Akkaraju S., Goodnow C.C., and Fearon S.T. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 271 (1996) 348-350
52. Toapanta F.R., and Ross T.M. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res 36 (2006) 197-210
53. Wagner C., Hansh G.M., Stegmaier S., Denefleh B., Hug F., and Schoels M. The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol 31 (2001) 1173-1180
54. Worth R.G., Mayo-Bond L., van de Winkel J.G., Todd RFr., and Petty H.R. CR3 (alphaM beta2; CD11b/CD18) restores IgG-dependent pahgocytosis in transfectants expressing a phagocytosis-defective Fc gammaRIIA (CD32) tail-minus mutant. J Immunol 157 12. (1996)
55. Yan J., Vetvicka V., Xia Y., Hanikyrova M., Mayadas T.N., and Ross G.D. Critical role of Kuffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan. Immunopharmacology 46 (2000) 39-54
56. Marth T., and Kelsall B.L. Regulation of interleukin-12 by complement receptor 3 signaling. J Exp Med 185 (1997) 1987-1995
57. van der Laan L.J., Ruuls S.R., Weber K.S., Lodder I.J., Dopp E.A., and Dijkstra C.D. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necorsis factor-alpha and nitric oxide. J Neuroimmunol 70 (1996) 145-152
58. Goodrum K.J., McCormick L.L., and Schneider B. Group B streptococcus-induced nitric oxide production in murine macrophages is CR3 (CD11b/CD18) dependent. Infect Immun 62 (1994) 3102-3107
59. Roizman B., Knipe D.M., and Whitley R.J. Herpes simplex virus. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 5th ed. (2007), Lippincott, Williams and Wilkins, Philadelphia 2501-2602
60. Kristensson K., Lycke E., Roytta M., Svennerholm B., and Vahlne A. Neuritic transport of herpes simplex virus in rat sensory neurons in vitro. Effects of substances interacting with microtubular function and axonal flow [nocodazole, taxol and erythro-9-3-(2-hydroxynonyl)adenine]. J Gen Virol 67 (1986) 2023-2028
61. Klein R.J., Friedman-Kien A.E., and Brady E. Latent herpes simplex virus in ganglia of mice after primary infection and reinoculation at a distant site. Archi Virol 57 (1978) 161-166
62. Price R.W., Waltz M.A., Wohlenberg C., and Notkins A.L. Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunication. Science 188 (1975) 938-940
63. Stevens J.G., and Cook M.L. Latent herpes simplex virus in spinal ganglia of mice. Science 173 (1971) 843-845
64. Garber D.A., Schaffer P.A., and Knipe D.M. A LAT-associated function reduces productive-cycle gene expression during acute infection of murine sensory neurons with herpes simplex virus type 1. J Virol 71 (1997) 5885-5893
65. Wang Q.-Y., Zhou C., Johnson K.E., Colgrove R.C., Coen D.M., and Knipe D.M. Herpesviral latency-associated transcript gene promotes assembly of heterochromatin on viral lytic-gene promoters in latent infection. Proc Natl Acad Sci USA 102 (2005) 16055-16059
66. Umbach J.L., Kramer M.F., Jurak I., Karnowski H.W., Coen D.M., and Cullen B.R. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 454 (2008) 780-783
67. Olson L.C., Buescher E.L., and Artenstein M.S. Herpesvirus infections of the human central nervous system. N Engl J Med 277 (1967) 1271-1277
68. Pepose J.S., Keadle T.L., and Morrison L.A. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J Ophthalmol 141 3 (2006) 547-557
69. Wald A., and Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185 (2002) 45-52
70. Manickan E., Francotte M., Kuklin N., Dewerchin M., Molitor C., Gheysen D., et al. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protecting immunity against herpes simplex virus through CD4+ Th1+ T cells. J Virol 69 (1995) 4711-4716
71. Yasukawa M., Inatsuki A., and Kobayashi Y. Helper activity in antigen-specific antibody production mediated by CD4+ human cytotoxic T cell clones directed against herpes simplex virus. J Immunol 140 (1988) 3419-3425
72. Smith P.M., Wolcott R.M., Chervenack R., and Jennings S.R. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-gamma. Virology 202 1 (1994) 76-88
73. Bouley D.M., Kanangut S., Wire W.S., and Rouse B.T. Characterization of herpes simplex virus type-1 infection and herpetic stromal keratitis development in IFN-gamma knockout mice. J Immunol 155 (1995) 3964-4741
74. Hayashida I., Nagafuchi S., Hayashi Y., Kino Y., Mori R., Oda H., et al. Mechanism of antibody-mediated protection against herpes simplex virus infection in athymic nude mice: requirement of Fc portion of antibody. Microbiol Immunol 26 (1982) 497-509
75. Ashley R.L., Dalessio J., Burchett S., Brown Z., Berry S., Mohan K., et al. Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. J Clin Invest 90 (1992) 511-514
76. Whitley R.J. Neonatal herpes simplex virus infections: is there a role for immunoglobulin in disease prevention and therapy?. Pediatric Infect Dis 13 (1994) 432-438
77. McKendall R.R. Delayed IgG-mediated clearance of herpes simplex virus type 1 from the CNS but not footpad during the early stages of infection: possible result of relative integrity of the blood-brain barrier. J Gen Virol 64 (1983) 1965-1972
78. Oakes J.E., and Lausch R.N. Role of Fc fragments in antibody-mediated recovery from ocular and subcutaneous herpes simplex virus infections. Infect Immun 33 (1981) 109-114
79. Morrison L.A., and Knipe D.M. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 68 (1994) 689-696
80. Spenlehauer C., Kirn A., Aubertin A.M., and Moog C. Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition. J Virol 75 (2001) 2235-2245
81. Edwards M.J., and Dimmock N.J. Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology 278 (2000) 423-435
82. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19 (2001) 197-223
83. Lubinski J., Nagashunmugam T., and Friedman H.M. Viral interference with antibody and complement. Semin Cell Dev Biol 9 (1998) 329-337
84. Sanna P.P., DeLogu A., Williamson R.A., Hom Y.L., Strauss S.E., Bloom F.E., et al. Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Virology 215 (1996) 101-106
85. Mester J.C., Glorioso J.C., and Rouse B.T. Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies. J Infect Dis 163 (1991) 263-269
86. McKendall R.R. IgG-mediated viral clearance in experimental infection with herpes simplex virus type 1: role for neutralization and Fc-dependent functions but not C' cytolysis and C5 chemotaxis. J Infect Dis 151 (1985) 464-470
87. Hook L.M., Lubinski J.M., Jiang M., Pangburn M.K., and Friedman H.M. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin m antibody. J Virol 80 (2006) 4038-4046
88. Hartung H.P., and Hadding U. Synthesis of complement by macrophages and modulation of their functions through complement activation. Springer Semin Immunopathol 6 (1983) 283-326
89. Brubaker J.O., Thompson C.M., Morrison L.A., Knipe D.M., Siber G.B., and Finberg R.W. Th1-associated immune responses to beta-galactosidase expressed by replication-defective herpes simplex virus. J Immunol 157 (1996) 1598-1604
90. Brockman M.A., and Knipe D.M. Herpes simplex virus vectors elicit a durable antibody response in mice despite the presence of preexisting host immunity. J Virol 76 (2002) 3678-3687
91. Da Costa X.J., Kramer M.F., Zhu J., Brockman M.A., and Knipe D.M. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 74 (2000) 7963-7971
92. Dudek T., and Knipe D.M. Replication-defective viruses as vaccines and vaccine vectors. Virology 344 (2006) 230-239
93. Hoshino Y., Pesnicak L., Dowdell K.C., Lacayo J., Dudek T., Knipe D.M., et al. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26 (2008) 4034-4040
94. Murphy C.G., Lucas W.T., Means R., Czajak S., Hale C.L., Lifson J.D., et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 74 (2000) 7745-7753
95. Kaur A., Sanford H.B., Garry D., Lang S., Klumpp S.A., Watanabe D., et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 357 2 (2007) 199-214
96. Koelle D.M., and Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 59 (2008) 381-395
97. Nagashunmugam T., Lubinski J., Wang L., Goldstein L.T., Weeks B.S., Sundaresan P., et al. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 72 (1998) 5351-5359
98. Friedman H.M., Wang L., Fishman N.O., Lambris J.D., Eisenberg R.J., Cohen G.H., et al. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J Virol 70 (1996) 4253-4260
99. Lubinski J.M., Wang L., Soulika A.M., Burger R., Wetsel R.A., Colten H., et al. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol 72 (1998) 8257-8263
100. Lubinski J.M., Jiang M., Hook L., Chang Y., Sarver C., Mastellos D., et al. Herpes simplex virustype 1 evades theeffects of antibody and complement in vivo. J Virol 76 (2002) 9232-9241
101. Mehlhop E., and Diamond M.S. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 203 (2006) 1371-1381
102. Suresh M., Molina H., Salvato M.S., Mastellos D., Lambris J.D., and Sandor M. Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol 170 (2003) 788-794
103. Lambris J.D., Ricklin D., and Geisbrecht B.V. Complement evasion by human pathogens. Nat Rev Microbiol 6 (2008) 132-142
104. Schauber-Plewa C., Simmons A., Tuerk M.J., Pacheco C.D., and Veres G. Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation. Gene Ther 12 (2005) 238-245